Is CAPR or CBIO more undervalued in 2026?

CirclFi compares Capricor Therapeutics, Inc. (CAPR) and Crescent Biopharma, Inc. (CBIO) using 13 institutional-grade valuation models. CAPR has a Quality of Company score of 6.9/10 while CBIO scores 5.3/10.

Which is a better buy — CAPR or CBIO?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CAPR and CBIO valuations compare?

CAPR at $29.11 and CBIO at $21.47 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CAPR vs CBIO Valuation Comparison 2026 — Intrinsic Value Analysis

CAPR

Biotechnology

Capricor Therapeutics, Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$29.11

Last close

Models

12/13

Active

CBIO

Biotechnology

Crescent Biopharma, Inc.

Quality

5.3

out of 10

Value Trap

SAFE

Price

$21.47

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	CAPR Fair Value	CAPR Upside	CBIO Fair Value	CBIO Upside
Bayesian DCF	Intrinsic	$6.67	-77.1%	$8.97	-58.2%
Earnings Power Value	Intrinsic	$15.35	-56.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.23	-99.3%	$4.01	-81.3%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CAPR vs CBIO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CAPR vs CBIO — Which Stock Is More Undervalued?

CAPR scores higher with a 6.9/10 quality rating vs CBIO's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Capricor Therapeutics, Inc. (CAPR) and Crescent Biopharma, Inc. (CBIO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CAPR currently trades at $29.11 with a QOC of 6.9/10, while CBIO trades at $21.47 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).